[Funding alert] Bolognese Biotech startup Cellply Secures €3.6 million in Funding

Read also - Annika Falkengren Joins Swedish Tech Company Ark Kapital’s Board of Directors

Additionally, they are eager to broaden their presence all through Europe. The long-term goal of Cellply is to be the industry pioneer in cell therapy study and quality standards. They expect significant staff turnover by the end of 2023 and a strong growth trajectory over the next two years.

Read also - Berlin-based Proptech Startup Novo Raises €1 million Pre-seed Funding

CEO Emiliano Spagnolo said: “We want to offer biotech and pharma companies and clinics that develop new cell therapies a tool capable of reducing development times, costs and risks.” and explained: “Our advanced robotic platform integrates a patented micro-fluidic device, effectively acting as an evaluation ring for individual cells. Using state-of-the-art technologies like machine learning and AI, we can assess each cell therapy batch in detail. This helps us identify samples with a higher count of potent cells, fast-tracking the creation of innovative therapies. Our ultimate goal is the ‘Cell Pass’, which tracks a product’s functional attributes throughout its lifecycle, an essential advancement for the cell therapy domain.”

They achieved significant achievements such as securing €2 million in 2021 and another €810K in 2022. The new company is focused on solidifying its position in the scientific and technological industry in order to expand to the US and North American markets. This is the outcome of these achievements.

Read also - Austrian-based Greenwood Power Secures €5.1 million in Funding

About Cellply

Massimo Bocchi and Roberto Guerrieri founded Cellply in 2013, and it stands out in the field of biotech for its expertise in evaluating the efficacy of immunotherapies for the treatment of cancer.

Read also - Amsterdam-based no -code Website Builder Framer Secures $27M in Series C Round Funding

CellPly's technologies have two goals in mind when it concerns their contributions to healthcare. They emphasize patient safety while ensuring the safety of pharmaceutical corporations' research investments. Immunotherapies, as opposed to traditional chemical-based treatments, utilise living cells, each of which has unique characteristics.

Read also - Hungary-based Startup Flawless Secures $2.2 Mn in Seed Funding